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and Marrow Transplantation2015 BMT Tandem Meetings Will Be Feb. 11-15
in San Diego, CaliforniaThe combined 2015 annual meetings
of ASBMT and the Center for Interna-
tional Blood and Marrow Transplant
Research (CIBMTR) will be Feb. 11-15 at
the Manchester Grand Hyatt in San
Diego, California.
Recent advances in the broad ﬁeld of
cellular therapy and blood and marrow
transplantation will be addressed in
plenary sessions, concurrent sessions,
oral abstracts, workshops, poster ses-
sions and symposia.
The scientiﬁc program chair for
ASBMT is Krishna V. Komanduri, MD of
the University of Miami Health System
in Miami, FL. and the scientiﬁc chair for
CIBMTR is Paul Veys, MBBS, of the
Great Ormond Street Hospital in Lon-
don, UK.
In addition to the ﬁve days of scien-
tiﬁc sessions for BMT clinicians and in-
vestigators, there will be other related
conferences and sessions (tentative
schedule is listed below):
 FACT Workshops for Applicant
Preparation and Inspector
Training e Feb. 10 (separate regis-
tration required)
 Clinical Research Professionals/
Data Managers e Feb. 10-11
 BMT CTN Coordinators/Invest-
igators e Feb. 11-12
 Fundamentals of HCT Training
Course/Pharmacy Boot Camp e
Feb 11-12 (separate registration
required)
 Pediatric BMT e Feb. 12
 BMT Center Administrators e Feb.
12-13
 BMT Pharmacists e Feb. 13-14
 Transplant Nursing e Feb. 13-15
 ASBMT President’s Conference e
Feb. 14
 BMT Clinical Education Confer-
ence (APPs, Fellows and Junior
Faculty) e Feb. 14-15
The deadline for early conference
registration and abstract submission is
Oct. 9. Online conference registration,1083-8791/$ e see front matter  2014 American Soc
http://dx.doi.org/10.1016/j.bbmt.2014.05.018abstract submission and housing reser-
vations will open in July and can be
accessed on both the ASBMT website,
www.asbmt.org, and the CIBMTR
website, www.cibmtr.org. Information
is updated continuously.
CLINICAL CASE FORUM IS
ENHANCING HOW DOCTORS
COLLABORATE
After the launch of the ASBMT Clin-
ical Case Forum in late February, we
have made some tremendous progress
with members using the site and post-
ing cases. Participants are already
collaborating on cases and realizing
positive clinical impacts for their pa-
tients, such as the case below, showing
the interaction between Dr. Bill Wood
and Dr. Mark Litzow.
Case Summary e 67 year old male
with atypical CML vs MDS/MPN
considering alloHCT:
Posted by
Bill Wood, MD, MPHBone Marrow and Stem Cell Trans-
plantation Program at University of
North Carolina at Chapel Hill
“This is a 67 year old male who was
in his usual state of excellent
health, walking 6-8 miles daily,
until he experienced fatigue and
decline in exercise tolerance in
early to mid 2013. By August 2013
he developed a 20-pound weight
loss, cough and left sided chest
pain. CBC at that time showed WBC
105,000 (predominantly neutro-
phils with rare blasts), hemoglobin
8 and platelet count of 161,000.
BCR/ABL and JAK-2 testing wereiety for Blood and Marrow Transplantation.negative.” You can view the entire
case details from Dr. Wood at
asbmt.medting.com.
Dr. Wood’s questions for the Forum
participants:
“1. Do you agree with pursuing a
RIC bu/ﬂu allogeneic stem cell
transplantation for this patient?
Why or why not?
2. In theory, transplantation could
occur within several weeks.
Depending on the results of the
bone marrow biopsy, what addi-
tional treatment, if any, would you
pursue prior to transplantation?”Mark R. Litzow, MDProfessor of Medicine and Chair,
Myeloid Disease Group, Division of He-
matology at Mayo Clinic
Dr. Litzow’s response:
“If one makes the assumption that
this is primary myeloﬁbrosis, one
could apply the DIPSS plus prog-
nostic scoring system and I think
this patient would have a score of 4
(I’m assuming he is RBC transfusion
dependent), giving him a median
survival of 16 months which I think
would justify transplant. A harder
question is whether to cytoreduce
or not. We have used 2-CDA in this
setting and have gotten good
cytoreduction, but I think it would
also be reasonable to take this pa-
tient directly to BMT.
Currently, we most commonly give
5 mg/m2 over 2 hours daily for
5 days. See Faoro, et al. Long-term
analysis of the palliative beneﬁt
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myeloﬁbrosis with myeloid meta-
plasia. Eur J Hem 74:117, 2005”
Dr. Wood’s patient impact feedback:
“The patient has had fantastic results
and Dr. Litzow’s advice directly
inﬂuenced my management of the
patient. Using cladribine in this caseis something he has had success
with, but not something I would
have immediately thought of.”
Please remember, ASBMT members
have complimentary access to the
Forum as a beneﬁt of joining the Society,
and non-members have access for a
limited time. You can choose how to
use the Forum, whether you want tosimply review or comment on inter-
esting BMT cases, post your own cases
for fast feedback, or network with BMT
colleagues.
We hope you review the interesting
cases in the ASBMT Clinical Case
Forum or use it to post your own
questions in this BMT exclusive com-
munity. Visit asbmt.medting.com for
more details.
